Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals (NASDAQ:REGN) shares fell over 3% in early Monday afternoon trading after it told investors that US net product sales of its franchise of Eylea totalled about $1.46 billion in the fourth quarter of 2023, below analysts' consensus estimates.  The figures for the eye drug were divulged in a presentation by the company at the  42nd Annual J.P.

Regeneron hints at 4Q US sales of Eylea below expectations

Apple

Cardinal Health

Everest Group Ltd

International Paper

The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.

5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016

Exelixis

Regeneron preannounced disappointing U.S. Eylea sales, while Exelixis issued light 2024 guidance. REGN stock and EXEL stock slumped.

Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes

Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in more than two dozen countries for various indications Medison and Regeneron will work together to continue patient access to this important therapy in select markets ZUG, Switzerland , Jan. 8, 2024 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today their exclusive multi-national agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, to commercialize Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in select European markets and additional markets around the world.   Libtayo was invented in laboratories at Regeneron, which acquired exclusive worldwide development, commercialization, and manufacturing rights to the medicine from Sanofi in July 2022.

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

Regeneron Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.34 billion in the United States in the fourth quarter.

Regeneron reports preliminary Q4 U.S. sales of Eylea at $1.34 bln

TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

BeiGene

Sarepta Therapeutics

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024

Moderna

Regeneron's key medicines and wide pipeline paint a bright future for the company. Moderna should recover, even after seeing its coronavirus-related sales plunge.

2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?

Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?

Wingstop

SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.

Best Momentum Stocks to Buy for January 3rd

Casey's General Stores

Shopify

Splunk

We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.

Top 5 Momentum Picks for January After a Fabulous 2023

Amazon

Booking Hlds

Chipotle

DexCom

Mastercard

Monolithic Power Systems

NVIDIA

Old Dominion Freight Line

Following a stellar 24.2% S&P 500 rally in 2023, investors debate what's next. But one thing investors agree on is this: Let your winners ride.

Top Investors Hang Onto These 11 Longtime Moneymaker Stocks

The recent launch of Eylea HD should lead to stronger sales growth for Regeneron next year. The company's hematology-oncology business could get a boost with a possible drug approval.

Where Will Regeneron Pharmaceuticals Be in 1 Year?

Applied Materials

Constellation Energy Corp

Charter Communications

Comcast

KLA-Tencor

QUALCOMM

Understandably, with the innovation sector printing a remarkable performance, all eyes have centered on Nasdaq-100 stocks. Indeed, on a year-to-date basis, the index shot up about 52%.

7 Undervalued Nasdaq-100 Stocks for Bargain Hunters

TARRYTOWN, N.Y., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

GlaxoSmithKline

Eli Lilly

Novo Nordisk

Vertex Pharmaceuticals

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

5 Big Drug Stocks That May Continue to Outperform in 2024

Alphabet

Coca-Cola

Coca-Cola offers investors the security of growing dividend payments. Alphabet and Regeneron have delivered long track records of growth -- and more is on the way.

It's Almost 2024: 3 Top Stocks to Buy Before the New Year

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) American Society of Hematology 2023 Investor Conference Call December 14, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Andres Sirulnik - Senior Vice President, Translational & Clinical Sciences, Hematology Conference Call Participants Beth Scott - TD Cowen Nicole Germino - Truist Securities Carter Gould - Barclays Malcolm Hoffman - BMO Capital Markets David Risinger - Leerink Partners Christopher Raymond - Piper Sandler Hartaj Singh - Oppenheimer and Company Operator Welcome to the Regeneron Pharmaceuticals' ASH 2023 Investor Conference Call. My name is Shannon and I'll be your operator for today's call.

Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)

Carnival

Regeneron Pharmaceuticals is a growing healthcare company with impressive margins and free cash flow. Carnival Corp. has been recovering from the pandemic and better days are ahead, even if leisure travel slows down next year.

3 Stocks to Buy Before 2024 That Can Set You Up For Life

TARRYTOWN, N.Y., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its inclusion on the Dow Jones Sustainability World Index (DJSI World) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index (DJSI North America). These consistent rankings reflect the company's continued dedication to sustainability and highlight Regeneron's belief that advancing environmental, social and governance (ESG) practices is fundamental to the long-term resiliency and ethical foundation of both our business and society as a whole.

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR)

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.

Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate

Alnylam Pharmaceuticals

Gilead Sciences

iShares Nasdaq Biotechnology ETF

The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally and turnaround off its 52-week lows.

News for Regeneron Pharmaceuticals Stock (REGN)